FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

The Ocata Preclinical Pipeline, Part 3: Mesenchymal Stem Cells




































Image Source: CELLMEDICINE

Summary

  • Ocata is a potential competitor in the mesenchymal stem cell space of regenerative medicine.
  • Mesenchymal stem cells represent a promising therapeutic strategy for a variety of immune-related diseases.
  • Favorable preclinical results have been reported by Ocata in models of multiple sclerosis, lupus, and other autoimmune disorders.

This article is the conclusion of my roundup of the current preclinical pipeline of Ocata Therapeutics. Parts 1 and 2 have been previously published, detailing Ocata's exploits in platelets and in retinal progenitors, and I have saved for last the preclinical developments that may loom largest for this company.

To be certain, Ocata is thoroughly entrenched in the retinal disease space. Its phase 2 trials in AMD and SMD are the most mature in the company's pipeline. However, many potential investors may be unaware of the preclinical developments in autoimmune disorders. Namely, their mesenchymal stem cell platform has shown some highly promising preclinical data, with validating grants from government agencies going to the company to forward this program. In this article, I'm going to provide some background into this technology, Ocata's experience so far, and where the company fits in the current market for these diseases.

What Are Mesenchymal Stem Cells?

The mesenchymal stem cell (NYSEARCA:MSC) is a multipotent cell type found in the bone marrow. It's able to form different types of cells that help form tissues like extracellular matrix and adipose. Importantly, it has been discovered that mesenchymal stem cells act in the body as an immune system regulator. Specifically, they suppress the tendency for T cells (the cells that provide an immune response to specific threats using antibody-dependent signaling) to recognize targets and attack. This suppression of T cell outgrowth has been suggested as a potential preventative in mouse models of autoencephalomyelitis.

How do MSCs do this? By expressing a variety of soluble factors, like interleukin-10 and gamma-interferon, which inhibit the promoters of inflammation. By suppressing a surge in immune response, it is hypothesized that MSCs can help prevent autoimmune disease.

Story Source: The above story is based on materials provided by SEEKINGALPHA
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News